7th International Symposium on
Meniere's Disease and Inner Ear Disorders
ROME ITALY October 17th-20th, 2015
Auditorium Antonianum
Dear Colleagues, dear Friends,

It is a great pleasure and honour for me to welcome all of you to the Seventh International Symposium on Ménière’s Disease and Inner Ear Disorders that will take place in Rome, Italy, from the 17th to the 20th of October, 2015.

This is the second time that this Symposium is held in Italy, and more specifically in Rome, after the 1993 Edition chaired by my mentor, professor Roberto Filipo. So, twenty-two years later, all the major experts of this fascinating speciality will gather again in the special magical atmosphere of the Eternal City to exchange opinions, discuss old data and propose new enlightening ideas.

Thanks to your active participation, this Symposium will hopefully offer high-quality scientific contents in the form of keynote lectures, invited speeches, round tables and posters, as well as social activities during which old friends will meet once more and new friendships and co-operations will develop.

This Symposium will also be highly technological and interactive with a dedicated App available for all the delegates during and after the Symposium, giving the possibility to listen to missed presentations, to post questions to the speakers or poster presenters, and more.

I hope the Symposium will fulfil the expectations that motivated more than 500 delegates to be present, in terms of scientific information to take home and spread within each local Otologic community. In simple words: a scientific event that was worthwhile! Thank you for being here.
President
Maurizio Barbara

Honorary President
Roberto Filipo

ADVISORY BOARD
Harris J., USA
Ito J., Japan
Lim D., USA
Rask-Andersen H., Sweden
Ryan A., USA
Zenner H-P., Germany

GUEST OF HONOUR
Paparella M.M, USA

ADVISORY INTERNATIONAL FACULTY
Anniko M., Sweden
Ardic F.N., Turkey
Arsovic N., Serbia
Bayazit Y., Turkey
Belal A., Egypt
Bento R., Brazil
Caye-Thomasen P., Denmark
Darrouzet V., France
Djeric D., Serbia
Duckert L., USA
Esteve-Frayssé M.J., France
Ferraro J., USA
Fraysse B., France
Gadre A., USA
Gantz B., USA
Guner EA., Turkey
Guyot J.P., Switzerland
Herman P., France
Hultcrantz M., Sweden
Hussl B., Austria
Incesulu A., Turkey
Jahnke K., Germany
Kameswaran M., India
Kania R., France
Kaplan D., Israel
Lacour M., France
Laszig R., Germany
Laurell G., Sweden
Lefebvre P., Belgium
Lenarz T., Germany
Linthicum FH., USA
Lopez Escamez J.A., Spain
Luntz M., Israel
Magnusson M., Sweden
McKenna M., USA
Michel O., Belgium
Möller P., Norway
O’Leary S., Australia
Oliveira C., Brazil
Ozgirgin N., Turkey
Perez N., Spain
Perez R., Israel
Plontke S., Germany
Profant M., Slovakia
Ramos Macias A., Spain
Saim L., Malaysia
Salt A.N., USA
Sannikorn P., Thailand
Schrott-Fischer A., Austria
Shojaku H., Japan
Shupak A., Israel
Skarzynski H., Poland
Somers T., Belgium
Sprinzl G., Austria
Sterkers O., France
Suzuki M., Japan
Takeda N., Japan
Tran Ba Huy P., France
Uruquiza R., Spain
Van de Heyning P., Belgium
Veldman J. The Netherlands
Wackym A., USA
Wazen JJ., USA

ADVISORY NATIONAL FACULTY
Albera R.
Benazzo M.
Berrettini S.
Bussi M.
Califano L.
Casani A.
Cassandro E.
Cesarani A.
Cuda D.
Fabiani M.
Fusetti M.
Leone C. A.
Mammano F.
Manfrin M.
Manzari L.
Neri G.
Nuti D.
Paludetti G.
Passali D.
Pirodda A.
Quaranta N.
Schoenhuber R.
Serra A.
Teggi R.
Zanetti D.

-2-

-3-
12.00-14.00 Registration

AUDITORIUM

14.30-15.00 MiniSymposium: Antisecretory Factor - a clinical innovation in Ménière’s disease?
(with the unconditional contribution from POA Pharmaceuticals, Sweden)

Moderator: J.G. Bruhn (Tomelilla, Sweden)

14.30-14.35 Antisecretory factor and medical foods - novel therapy concepts
J.G Bruhn (Tomelilla, Sweden)

14.35-14.45 Antisecretory factor-inducing therapy improves patient-reported functional levels in Ménière’s disease
S.C. Leong, T.H. Lesser (Liverpool, UK)

14.45-14.55 SPC Flakes in prophylaxis of Menière’s disease
R. Tegni, V. Marcelli (Milano, Italy)

15.15-15.55 Is there any place for medical treatment in BPPV?
How much vitamin D levels affect?
E. Alpin Guneri (Izmir, Turkey)

15.55-16.10 Posterior canal involvement. How is it diagnosed and treated?
Why does it occur so often?
M. Mandalà (Siena, Italy)

16.10-16.25 Lateral SSC apogeotropic nystagmus. What is the difficulty in it?
Why do new manoeuvres come out. What is the best treatment
D. Nuti (Siena, Italy)

16.25-16.40 Are the canalith repositioning manoeuvres effectively treat BPPV once?
What to do following the manoeuvre?
Are there any precautions to be instructed the patient?
When should we consider surgery?
V. Darrouzet (Bordeaux, France)

17.00-18.30 Opening Ceremony

17.45-18.30 Opening Lecture: Meniere’s Disease
(Cause, Pathogenesis and Symptoms of Meniere’s Disease)
M.M. Paparella (Minneapolis, USA)

19.00-21.30 Welcome Cocktail (Palazzo Brancaccio)

19.30-19.45 Vertigo: from Daedalus to Meniere
D. Lippi (Florence, Italy)
**SUNDAY OCTOBER 18TH, 2015**

**AUDITORIUM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-08.10</td>
<td>Introductory Message</td>
<td>M. Barbara (Rome, Italy)</td>
</tr>
<tr>
<td>08.10-08.25</td>
<td>KEYNOTE LECTURE 1</td>
<td>M. Barbara (Rome, Italy)</td>
</tr>
<tr>
<td>08.30-09.30</td>
<td>HUMAN PATHOLOGICAL FINDINGS</td>
<td>B. Hussl (Innsbruck, Austria), M.M. Paparella (Minneapolis, USA)</td>
</tr>
<tr>
<td>08.30-08.43</td>
<td>The Histopathology of Ménière's Disease: Observations from the Temporal Bone Collection at the Massachusetts Eye and Ear Infirmary</td>
<td>M. McKenna, J.B. Nadol (Boston, USA)</td>
</tr>
<tr>
<td>08.45-08.58</td>
<td>Ultrastructure and Immunohistochemistry of the Human Inner Ear Relevant for Ménière's Disease</td>
<td>A. Schrott-Fischer, W. Liu, R. Glueckert, H. Rask-Andersen (Innsbruck, Austria/Uppsala, Sweden)</td>
</tr>
<tr>
<td>09.00-09.13</td>
<td>Clinical significance of Bast's valve</td>
<td>A. Belal (Alexandria, Egypt)</td>
</tr>
<tr>
<td>09.15-09.28</td>
<td>Role of human ES in the pathogenesis of Ménière's disease: human temporal bone study</td>
<td>F.H. Linthicum, D.J. Lim (Los Angeles, USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>KEYNOTE LECTURE 2</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30-09.50</td>
<td>Cochlear proteomics of fluid and ion transport</td>
<td>R. Filipo (Rome, Italy), A. Belal (Alexandria, Egypt)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A.F. Ryan (San Diego, USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>PATWAYS TO THE INNER EAR</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-10.28</td>
<td>Gentamicin Distribution in the Ear Following Local Applications</td>
<td>A.N. Salt, F.B. Kraus, E.B. King, S.K. Plontke (St. Louis, USA)</td>
</tr>
<tr>
<td>10.15-10.28</td>
<td>Drug delivery via the oval window</td>
<td>S. O'Leary, E. King, J. Fallon, D. Brown, A.N. Salt (Melbourne, Australia/St Louis, USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Coffee break</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30-11.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>KEYNOTE LECTURE 3</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00-11.20</td>
<td>Human Endolymphatic Duct System, Transepithelial Water Channels and Cochlear Ultrastructure</td>
<td>S. O'Leary (Melbourne, Australia), A. Schrott-Fischer (Innsbruck, Austria)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H. Rask-Andersen, W. Liu (Uppsala, Sweden)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>BLOOD PERILYMPH BARRIER</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30-11.48</td>
<td></td>
<td>K. Jahnke, D. Arweiler-Harbeck (Essen, Germany)</td>
</tr>
<tr>
<td>11.40-11.48</td>
<td></td>
<td>K. Hirose, S-Z Lee, J. Hartsock, A.N. Salt (St Louis, USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>The fine structure of the blood-perilymph barrier under normal, experimental and pathological conditions. An overview</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30-11.38</td>
<td></td>
<td>K. Jahnke, D. Arweiler-Harbeck (Essen, Germany)</td>
</tr>
<tr>
<td>11.40-11.48</td>
<td></td>
<td>K. Hirose, S-Z Lee, J. Hartsock, A.N. Salt (St Louis, USA)</td>
</tr>
</tbody>
</table>
12.00–13.15  THE FUNCTION OF THE ENDOLYMPHATIC SAC

**Moderator:**  D.J. Lim (Los Angeles, USA)

12.05–12.15  A new murine model for Ménière’s disease – vasopressin induced endolymphatic hydrops

M. Takumida, Y Katagiri, M. Anniko (Hiroshima, Japan; Uppsala, Sweden)

12.20–12.30  Ultrastructure and gene expression in the human endolymphatic sac – novel evidence of multiple functions

M. Müller, S. Kirkeby, K. Quorstrup, J. Vikeså, F.C. Nielsen, P. Caye-Thomsen (Copenhagen, Denmark)

12.35–12.45  Ion transport in the endolymphatic sac epithelial cells on the basis of experimental animal researches

N. Mori, T. Miyashita (Osaka, Japan)

12.50–13.00  Potassium secretion via apical multiple potassium channels in human endolymphatic sac epithelium

S.H. Kim, B.G. Kim, J.S. Jung, J.Y. Choi (Seoul, Korea)

13.05–13.15  Meniere’s Disease histopathological analysis: novel ultrastructural, molecular and MRI findings

G. Ishiyama, I. Lopez, A. Ishiyama (Los Angeles, USA)

---

11.50–13.25  REGENERATION, PROTEOMICS AND GENETICS

**Moderators:**  F. Mammano (Rome, Italy), JA Lopez-Escamez (Granada, Spain)

11.50–12.03  Histological and functional analysis of xenograft stem cells of the inner ear of mice in the guinea pig cochlea-induced hearing loss


12.05–12.18  Characterization and gene expression profile of an induced pluripotent stem cell model for familial Meniere’s Disease

S. Cabrera, A-R Ji, V. Ramos-Meja, T. Romero, L. Frejo, P. Real, J.A. Lopez-Escamez (Granada, Spain)

12.20–12.33  Confocal imaging of stimulus-independent action potential activity in the developing cochlea

F. Ceriani, S. Johnson, W. Marcotti, F. Mammano (Rome, Italy–UK)

12.35–12.43  HES-1 and coup-TFI SHRNA knocking down give rise to new hair cells and supporting cells in organ of Corti organotypic culture

J. Oiticica, A.C. Batissoco, K. Lezirovitz, M.M. Bissoli, D. Zanatta, B. Strauss, RC. Mingroni-Netto, L. Haddad, R.F. Bento (San Paulo, Brazil)

12.45–12.53  Heterozygous mutations in DTNA and FAM136A genes in familial Meniere’s Disease

T. Requena, S. Cabrera, C. Martin-Sierra, L. Frejo, S. D. Price, A. Lysakowski, J.A. Lopez-Escamez (Granada, Spain)

12.55–13.03  A proteomics based approach in Ménière Disease

E. Cassandro, C. Petrolo, G. Curdy, A. Scarpa, G. Sequino, G. Chiarella (Catanzaro/Salerno, Italy)

13.05–13.13  Role of oxidative stress in the cochlear damage in acquired sensorineural hearing loss: animal model lesson

A.R. Feconi, F. Paciello, R. Rolesi, S. Eramo, D. Troiani, G. Paludetti (Rome, Italy)

13.15–13.23  Altered chromogranin-A circulating levels in Ménière’s Disease

R. Torti, B. Colombo, M. Tramarchi, M. Bianco, A. Manfredi, M. Busi, A. Corti (Milano, Italy)
AUDITORIUM

13.30-14.20  SYMPOSIUM ON ELECTRICAL VESTIBULAR STIMULATION
(with the unconditional contribution from Medel, Innsbruck, Austria)

Moderator:  H. Rask-Andersen (Uppsala, Sweden)

13.30-13.40  High Resolution Micro CT Scanning of the Human Labyrinth to
Assess Anatomical Variability for a Vestibular Electrode Design
R. Gluckert, L. Johnson Chacko, M. Gloesmann, S. Handschuh,
A. Schrott-Fischer (Innsbruck, Vienna, Austria)

13.40-13.50  Vestibular implant for sensory restoration – Candidacy and
Epidemiology
B.K. Ward, D.Q. Sun, Y.R. Semenov, C.C. Della Santina (Baltimore, USA)

13.50-14.00  The vestibular implant: towards a clinically useful device
R. van de Berg, N. Guinand, J.P. Guyot, R. Stokroos, H. Kingma,
A. Perez-Fornos (Maastricht, The Netherlands; Geneve, Switzerland; Tomsk, Russia)

14.00-14.10  Vestibular implant: 12 years of development in the human
J.P. Guyot (Geneve, Switzerland), A. Perez-Fornos, N. Guinand, M. Miffon, R. Van de Berg,
R. Stokroos, H. Kingma; (Geneve, Switzerland, Maastricht, The Netherlands)

14.10-14.20  Discussion

PRESS ROOM

13.30-14.20  BUSINESS MEETING  (by invitation only)

AUDITORIUM

14.30-14.50  KEYNOTE LECTURE 4
Moderator:  A. Ryan (San Diego, USA)
Regenerative medicine for the inner ear
J. Ito (Kyoto, Japan)

15.00-16.30  AUDIOLOGICAL DIAGNOSTICS
Moderators:  R. Urquiza (Malaga, Spain), E. Cassandro (Salerno, Italy)

15.00-15.13  On the role on depletive tests: a review analysis
E. Covelli, S. Monini, M. Barbara (Rome, Italy)

15.15-15.28  Sensitivity of electrocochleography vs. otoacoustic emissions to
disrupted cochlear homeostasis in Menière patients
P. Avan, Y. Pavier, T. Mom, F. Giraudet (Clermont Ferrand, France)

15.30-15.43  Use of multifrequency admittancemetry associated to glycercol test to
assess hydrops – Normative values in healthy subjects
V. Franco-Vidal, D. Bonnard, J. Nodimar, V. Darrouzet (Bordeaux, France)

15.45-15.58  Sensitivity and Specificity of ECochG, VNG, VEMP, and Rotary Chair
in the Diagnosis of Meniere's Disease
J. Ferraro (Overland Park, USA)

16.00-16.13  Electrocochleography and vestibular evoked myogenic potential in
Meniere's Disease
S. Dabiri Satri, N. Yazdani, P. Abolhasani, B. Amirzaghar, N. Rezazadeh (Tehran, Iran)

16.15-16.28  Retrospective evaluation of hydrops diagnostic on Menière's Disease
T. Lenarc (Hannover, Germany)
15.00-16.30 VESTIBULAR DIAGNOSTICS

Moderators: A. Bozorg-Grayely (Dijon, France), D. Nuti (Siena, Italy)

15.00-15.13 Ocular and cervical vestibular-evoked myogenic potentials to air conducted sound and bone conducted vibration in Ménière’s Disease
I. Manzari, A.M. Burgess, H. MacDougall, I.S. Curthoys (Cassino, Italy/Sydney, Australia)

15.15-15.28 Vestibular evoked myogenic potentials in Ménière’s Disease
O. Çelik, B. Serbetsçioğlu, G. Eskiizmir (Istanbul, Turkey)

15.30-15.43 Ocular (o-VEMP) and Cervical (c-VEMP) VEMPs in Patients with "Clinically Certain" Meniere’s Disease
S. Mcllhinney, G. O’Beirne, J. Gourley, J. Hornibrook (Christchurch, New Zealand)

15.45-15.58 Normal video head impulse test with abnormal caloric irrigation test in definite Ménière’s disease: a potential new criteria for diagnosis?
F. Rubin, R. Kania, B. Verrillaud, C. Hautefort, P. Herman (Paris, France)

16.00-16.13 Instrumental Assessment in Menière’s Disease: Which Role for video Head Impulse Test?
A.P. Casani, N. Cerchiai, E. Navari (Pisa, Italy)

16.15-16.28 Ocular VEMP findings in patients with Ménière’s Disease
F. Kocyigit, B. Mutlu, Y. Olgun, S. Mungan Durankaya, E. Alpin Guner, G. Kirkim (Izmir, Turkey)

16.30-17.00 Coffee break

17.00-18.30 IMAGING

Moderators: A. Pirodda (Bologna, Italy), B. Fraysse (Toulouse, France)

17.00-17.13 A reappraisal of Menière’s disease supported by variable latency of symptoms and MRI visualization of the endolymphatic hydrops
I. Pyykkö, J. Zou, T. Nakashima, T. Yoshida, S. Naganawa (Tampere, Finland/Nagoya, Japan)

17.15-17.23 Endolymphatic hydrops in patients with unilateral and bilateral Meniere’s Disease

17.25-17.33 MRI evaluation of endolymphatic hydrops and clinical applications for surgical management

17.35-17.43 MR Imaging of Inner Ear Endo-perilymphatic Spaces at 3 Tesla after Intratympanic Contrast Agent Administration in Definite Meniere’s Disease
S. Salice, A. Tartaro, G. Filograna Pignatelli, A. Pacella, F. Cazzato, G. Neri (Chieti, Italy)

17.45-17.53 MRI Inner Ear Imaging and Tone Burst Electrocochleography in the Diagnosis of Meniere’s Disease
J. Hornibrook, E. Flook, S. Greig, M. Coates, R. Care, P. Bird (Christchurch, New Zealand)

17.55-18.03 Imaging of endolymphatic space in patients with Meniere’s Disease and non-otological diseases
T. Yoshida, M. Sone, K. Morimoto, S. Naganawa, T. Nakashima (Nagoya, Japan)

18.05-18.13 Understanding Meniere’s disease: the contribution of hydrops- MRI
K. Orimoto, S. O’Leary (Sydney, Australia)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 18.15-18.23 | Endolymphatic space size in patients with vestibular migraine and Meniere’s Disease  
| 18.30-19.30 | **SYMPOSIUM “INTRATYMPANIC DEXAMETHASONE AS A TREATMENT FOR MÉNIÈRE’S DISEASE”**  
|           | (with the unconditional contribution from Otonomy inc., USA) |
| **Moderator:** | J. Phillips (Norwich, UK) |
| 18.30-18.43 | Intratympanic dexamethasone as a treatment for Ménière’s Disease  
|           | J. Phillips (Norwich, UK) |
| 18.45-18.58 | Perilymph pharmacokinetics of glucocorticosteroids after intratympanic, intracochlear, and intralabyrinthine delivery  
|           | S. Plantke, A.N. Salt (Halle, Germany; St. Louis, USA) |
| 19.00-19.13 | Results from a Phase 2b Clinical Trial to Assess the Safety and Efficacy of Extended-Release Dexamethasone Thermosensitive Gel for Intratympanic Administration in Subjects with Ménière’s Disease  
|           | P. Lambert, C. LeBel (Charleston-San Diego, USA) |
| 19.15-19.28 | Discussion |
18.30-19.30 **ENDOLYMPHATIC HYDROPS**

**Moderators:** G. Paludetti, *(Rome, Italy)*, M.M. Paparella, *(Minneapolis, USA)*

18.30-18.38 Hormonal regulation of potassium in the inner ear, a new explanation of Ménière’s crisis

18.40-18.48 Imaging Fluid Dynamics in the Hydropic Ear with Light Sheet Fluorescence Microscopy
- D.J. Brown, L. Van Roon, C.L. Southwell, C.S. Pastras, I.S. Curthoys *(Sidney, Australia; Utrecht, Netherlands)*

18.50-18.58 Meniere’s symptoms and endolymphatic hydrops
- C.A. Oliveira *(Brasilia, Brazil)*

19.00-19.08 Are there NO news about the cochlear hydrops?

19.10-19.18 Anterior membranous labyrinth hydrops
- S. Ferrara, F. Martines, P. Ferrara *(Palermo, Italy)*

19.20-19.28 Oxidative Stress, Redox Homeostasis and Cellular Stress
- A. Serra, S. Cocuzzza, P. di Mauro, L. Maiolino *(Catania, Italy)*

**AUDITORIUM**

**MONDAY OCTOBER 19th, 2015**

**08.00-08.20** **KEYNOTE PRESIDENTIAL LECTURE 5**

**Moderators:** J. Ito *(Kyoto, Japan)*, F. Ottaviani *(Rome, Italy)*

15 years of intratympanic pressure treatment in disabilitating Méniere’s Disease
- M. Barbara *(Rome, Italy)*

**08.30-09.30** **IMMUNE SYSTEM AND MENIERE’S DISEASE**

**08.30-08.43** Local treatment of immune-mediated hearing loss by anti-TNF alpha drugs
- P. Lefebvre, S. Barriat, F. Van Wijck *(Liege, Belgium)*

**08.45-08.53** A locus in chromosome 6p21.33 associated with bilateral sensorineural hearing loss may define immuno-mediated variant in Méniere’s Disease
- JA Lopez Escamez, S. Cabrera, T. Requena, C. Martin-Sierra, L. Frejo, A. Batuecas, J.M. Espinosa-Sanchez *(Granada, Spain)*

**08.55-09.03** Neutrophil-to-lymphocyte ratio and platelet to lymphocyte ratio in patients with acute Méniere’s Disease
- V. Squeo, P.T. D’Ambruoso, N. Quaranta *(Bari, Italy)*

**09.05-09.13** Autoimmunity as a Candidate for the Etiopathogenesis of Ménière’s Disease: Detection of Autoimmune Reactions and Diagnostic Biomarker Candidate

**09.15-09.23** Experience of immunological aspects of Meniere’s Disease
- A. Nacci, L. Matteucci, B. Fattori, S.O. Romeo, S. Berrettini *(Pisa, Italy)*
**SAN FRANCISCO HALL**

**08.30–09.30** BARANY SYMPOSIUM: FROM MOUSE MODELS TO CLASSIFICATION OF MB MÉNIÈRE

**Moderator:** G. Laurell (Uppsala, Sweden)

**08.30–08.40** The regenerating inner ear

H. Rask-Andersen (Uppsala, Sweden)

**08.45–08.55** Experimental induced hydrops – in vivo studies in mice

M. Magnusson (Lund, Sweden)

**09.00–09.10** Classification of Mb Meniere, a progress report

J.A. Lopez-Escamez (Granada, Spain)

**09.15–09.25** IT therapy for MD

M. Magnusson (Lund, Sweden)

**AUDITORIUM**

**09.30–09.50** KEYNOTE LECTURE 6

**Moderators:** PP Lefebvre (Liège, Belgium), R. Albera (Turin, Italy)

Cerebral venous insufficiency in Ménière’s Disease

R. Filipo (Rome, Italy)

**10.30–11.00** Coffee break

**SAN FRANCISCO HALL**

**10.00–10.30** VESTIBULAR MIGRAINE

**Moderators:** B. Ceramic (London, UK), M. Anniko (Uppsala, Sweden)

**10.00–10.08** Vertiginous migraine and Ménière’s Disease

CA Oliveira, RL Bezerra, C. Messias, F. Bahmad Jr. (Brasilia, Brazil)

**10.10–10.18** Vestibular Migraine in an Otolaryngology Clinic: Prevalence, Associated Symptoms, and Prophylactic Medication Effectiveness

A. Van Omeringen, V. van Rompey, P. Van de Heyning, F.J. Wuys (Antwerp, Belgium)

**10.20–10.28** Vestibular assessment in Meniere’s disease and Migraine

B. Cakir, O. Yilmaz, H. Dizdar, Y. Bayazit (Istanbul, Turkey)

**10.30–11.00** Coffee break

**AUDITORIUM**

**11.00–12.15** JAPANESE SOCIETY OF EQUILIBRIUM RESEARCH (JSER) SYMPOSIUM

**Moderator:** M. Suzuki (Tokyo, Japan)

**11.00–11.15** Introduction

M. Suzuki (Tokyo, Japan)

**11.15–11.30** Epidemiological characteristics of Meniere’s disease in Japan

H. Shiojku, Y. Watanabe, H. Takakura, M. Tsubota, M. Fujisaka, M. Suzuki2, N. Takeda (Toyama, Tokyo, Tokushima, Japan)

**11.30–11.45** Diagnosis 1: Diagnostic standard for Meniere’s disease based on the clinical guideline of the disease in Japan

Y. Watanabe (Toyama, Japan)
11.45-12.00 Diagnosis 2: Diagnosis of endolymphatic hydrops using 3T MRI in patients with Meniere’s Disease
S. Usami, H. Yoshimura, H. Fukuoka, K. Tsukada (Matsumoto, Japan)

12.00-12.15 Overview of the treatment of Meniere’s Disease in Japan
I. Koizuka (Kawasaki, Japan)

12.30-13.20 VESTIBULAR REHABILITATION
Moderators: L. Duckert (Seattle, USA), D. Cuda (Piacenza, Italy)

12.30-12.43 Principles of long-term vestibular rehabilitation
M. Lacour (Marseille, France)

12.45-12.53 Role of perineuronal nets in vestibular compensation
F. Dagna, A. Albera, D. Carulli, A. Faralli, F. Rossi, P. Giordano, R. Albera (Turin, Italy)

12.55-13.03 Development of vestibular rehabilitation platform using immersive virtual reality system
S.K. Hong, CG Song, HJ Jeon (Seoul, Korea)

13.05-13.13 Reduction of time constant by a novel vestibular habituation: Possibility as a potent countermeasure for treatment of patients with motion sickness
S.K. Hong, H.J. Lee, H.J. Kim (Chuncheon, Korea)

11.00-12.30 SUDDEN HEARING LOSS & PERILYMPHATIC FISTULA & OTOTOXICITY
Moderators: M. Fabiani (Rome, Italy), N. Arsovic (Beograd, Serbia)

11.00-11.08 Otoacoustic emissions in sudden sensorineural hearing loss
A. Shupak, R. Zeidan, R. Shemesh (Haifa, Israel)

11.10-11.18 MRI findings and compliance to perform MRI in patients with SSNHL
R. Khniefes, N. Yehudai, S. Masud, M. Luntz (Haifa, Israel)

11.20-11.28 Effect of the hearing level of nonaffected ear and severity of acute hearing loss in patient with unilateral sudden deafness from the perspective of tinnitus
I. Čvorović, D. Djerić, A. Jotić (Beograd, Serbia)

11.30-11.38 Long term transtympanic steroid treatment results in patients with acute cochlear hearing loss
M. Durmusoğlu, Y. Olgun, E. Dogan, M.A. Kozen, E.A. Guneri (Izmir, Turkey)

11.40-11.48 The Spontaneous Perilymph Fistula Conundrum – Do we finally have an answer?
A.K. Gadre, I. Edwards, C. Rutledge-Roof (Louisville, USA)

11.50-11.58 Chronic disequilibrium as main symptom of bilateral perilymph fistula - case presentation
N. Arsovic, D. Pavlovic (Beograd, Serbia)

12.00-12.08 Intratympanic dexamethasome: potential in the prevention of cisplatin ototoxicity
A. Shupak, T. Marshak, L. Levi, M. Steiner (Haifa, Israel)

12.10-12.18 Analysis of genetic and non genetic risk factors for cisplatinum ototoxicity in pediatric patients
12.30-13.25  **DEHISCENCE SYNDROME**

**Moderators:** M. McKenna (Boston, USA), M. Fusetti (L’Aquila, Italy)

12.30-12.43  Otic Capsule Dehiscence Syndrome: Longitudinal Cognitive and Neurobehavioral Functional Outcomes Before and After Repair  
P.A. Wackym, C.D. Balaban, H.T. Mackay (Pittsburg, USA)

12.45-12.53  Trans-mastoid repair of superior semicircular canal dehiscence  
T. Somers, Y. C. Zhao, J. Husseman, J. van Dinther, R. Vanspauwen, R. Briggs (Antwerp, Belgium / Melbourne, Australia)

12.55-13.03  Superior canal dehiscence and "near-dehiscence" syndrome: clinical and instrumental aspects  
C. Brandolini, A. Castellucci, G. Piras, A. Firola (Bologna, Italy)

13.05-13.13  Ocular vestibular evoked myogenic potentials to high frequencies show semicircular canal dehiscence  
L. Manzari, AM Burgess, H. MacDougall, IS Curthoys (Cassino, Italy/Sydney, Australia)

13.15-13.23  Hearing outcome after transmastoid semicircular canal plugging  
V. Van Rompaey, G. Van Haesendonck, P. Van de Heyning (Antwerp, Belgium)

13.30-14.20  **CONTROVERSIAL ASPECTS OF THE CLINICAL STUDIES ON THE USE OF BETAHISTINE IN MÉNIÈRE’S DISEASE**  
(with the unconditional contribution from BGP Products srl, Italy)

**Moderator:** M. Barbara (Rome, Italy)

13.30-13.40  Epidemiology, statistics and research design  
R. Schoenhuber (Bozen, Italy)

13.40-13.50  MD patients in the acute stage  
A. Casani (Pisa, Italy)

13.50-14.00  MD patients in the intercritic stage  
N. Ozgirgin (Ankara, Turkey)

14.00-14.10  MD patients under rehabilitation  
M. Lacour (Marseille, France)

14.10-14.25  Discussion

14.30-15.20  **IT GENTAMYCIN TREATMENT**

**Moderators:** A. Shupak (Haifa, Israel), L. Manzari (Cassino, Italy)

14.30-14.38  Intratympanic gentamicin for definitive treatment of Meniere’s Disease: a series of 105 patients  
G. Russo, R. Grasias, F. Mosca, C. A. Leone (Naples, Italy)

14.40-14.48  Hearing loss following intratympanic gentamicin  
D. Kaplan (Omer, Israel)

14.50-14.58  Intratympanic gentamicin treatment. How to control therapeutic effects? How to respect otolith and cochlear function?  
P. Lorin, M. Donnard (Le Mans, France)
15.00-15.08 Long term vestibular function evolution after gentamycin intra tympanic injection
MJ Esteve Fraysse, S. Nicolas, A. Weckel, B. Lepage, M Marx, B Fraysse
(Toulouse, France)

15.10-15.18 Monitoring of chemical labyrinthectomy by gentamicin injection assessed by video head impulse test and VEMPs in patients suffering from Meniere disease resistant to medical therapies
C. de Waal, E. Chiarovano, G. Lamas, C. Magnani, H. MacDougall, I. Curthoys
(Paris, France/Sydney, Australia)

SAN FRANSISCO HALL

14.30-15.20 BPPV

Moderators: D. Bernardeschi (Paris, France), N. Quaranta (Bari, Italy)

14.30-14.38 Spontaneous inversion of nystagmus without a positional change in the horizontal canal variant of benign paroxysmal positional vertigo

14.40-14.48 The effects of hearing dysfunction in BPPV patients

14.50-14.58 Impact of cupulolithiasis on patients' well being
A. Abid, R. Yousef, T. Tomanovic (Stockholm, Sweden)

15.00-15.08 New theory of BPPV pathology "cristolithiasis" - Otoconia attached to the crista ampullaris

15.10-15.18 Benign Paroxysmal Positional Vertigo Prevalence in Meniere’s Disease: Is Meniere’s Disease a Predisposing Factor?
S. Nemati, A. S. Ali, M. Motasaddi-Zarandi, R. Panahi, M. Akbari (Rasht, Tehran, Iran)

AUDITORIUM

15.30-16.30 IT STEROID TREATMENT

Moderator: R. Laszig (Freiburg, Germany), C.A. Leone (Neaples, Italy)

S. Plontke, A. Liebau, O. Pogorzelski, A.N. Salt (Halle, Germany/St Louis, USA)

15.45-15.53 Glucocorticoids stimulate endolymphatic water reabsorption in inner ear

15.55-16.03 Comparison of Intra-Tympanic Steroid Therapy Protocols for Meniere’s Disease between Centers in Three Mediterranean Countries
R. Perez, S. Battelino, A. Incesulu (Jerusalem, Israel/ Ljubljana, Slovenia/Meselik Eskisehir, Turkey)

16.05-16.13 Evaluation of long term effect of intratympanic dexamethasone therapy (ITD) in Meniere’s Disease (MD)
C. Candreia, A. Lehner, M. Gartner, T. Linder (Luzern, Switzerland)

16.15-16.28 Intra-tympanic dexamethasone in the treatment of disabling vertigo in Meniere Disease
J.J. Wazen (Sarasota, USA)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Topic</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30-16.30</td>
<td><strong>CLINICAL ISSUES 1</strong></td>
<td>SAN FRANCISCO HALL</td>
<td>Idiopathic acute labyrinthine diseases and Meniere disease: the necessity of a multidisciplinary approach.</td>
<td>A. Pirodda, C. Brandolini, C. Borghi (Bologna, Italy)</td>
</tr>
<tr>
<td>16.00-16.08</td>
<td><strong>THE SOCIAL IMPACT OF MENIERE'S DISEASE: THE ROLE OF DIFFERENT TREATMENT STRATEGIES</strong></td>
<td>SAN FRANCISCO HALL</td>
<td>The natural history of MÉNIÈRE'S Disease: a systematic review</td>
<td>J. Bewick, D. Hoare, J. Phillips (Norwich, Nottingham, UK)</td>
</tr>
<tr>
<td>16.20-16.28</td>
<td>HIGH FREQUENCY DEAFNESS WITH VESTIBULAR EPISODIC SYNDROME</td>
<td>SAN FRANCISCO HALL</td>
<td>High frequency deafness with vestibular episodic syndrome</td>
<td>E. Martin-Sanz, J. Esteban, R. Sanz (Madrid, Spain)</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td><strong>COFFEE BREAK</strong></td>
<td>SAN FRANCISCO HALL</td>
<td>Vestibular Implant, a new approach to bilateral vestibular dysfunction</td>
<td>A. Ramos, A. Krah, M. Barbera, M. Manrique, E. Offeciers, A. Zarowski, N. Perez, J. Benitez, M. Killian (European Multicenter Project)</td>
</tr>
<tr>
<td>17.00-17.13</td>
<td>VESTIBULAR IMPLANT, A NEW APPROACH TO BILATERAL VESTIBULAR DYSFUNCTION</td>
<td>AUDITORIUM</td>
<td>Ménière's Disease: what can we learn from vestibular implants</td>
<td>J.T. Rubinstein, J.O. Phillips, L. King, K. Nie (Seattle, USA)</td>
</tr>
<tr>
<td>17.30-17.38</td>
<td>SUBJECTIVE VISUAL VERTICAL IN BILATERAL VESTIBULAR LOSS ROLE OF PROPRIOCEPTION</td>
<td>AUDITORIUM</td>
<td>Subjective visual vertical and horizontal in the Indian Population</td>
<td>G.A. Amit, K. Tyagi, A.M. Augustine, A. Leche, A. Bairaj (Vellore, India)</td>
</tr>
<tr>
<td>18.00-18.08</td>
<td>IMPROVING DIAGNOSTICS IN PATIENTS WITH VESTIBULAR PAROXYSMIA TO TREAT THEM IN AN EARLIER PHASE OF ILLNESS</td>
<td>AUDITORIUM</td>
<td>Improving diagnostics in patients with vestibular paroxysmia to treat them in an earlier phase of illness</td>
<td>B. Ihtijarevic, V. Van Rompaey, P. van den Heyning, F. Wuyts (Antwerp, Belgium)</td>
</tr>
<tr>
<td>18.30-18.38</td>
<td>A COMPARISON OF NEUROTLOGICAL AND PSYCHOMETRIC TEST RESULTS IN MÉNIÈRE'S DISEASE AND PHOBIC POSTURAL VERTIGO</td>
<td>AUDITORIUM</td>
<td>A comparison of neurotological and psychometric test results in MÉNIÈRE'S DISEASE and phobic postural vertigo</td>
<td>L. Nimroda, L. Kise, M. Nimroda (Riga, Latvia)</td>
</tr>
</tbody>
</table>
SAN FRANCISCO HALL

17.00-18.40 CLINICAL ISSUES 3

Moderators: R.F. Bento (San Paolo, Brazil), D. Zanetti (Milano, Italy)

17.00-17.08 eHealth in Meniere's disorder improves quality of life when medical therapy is not enough
I. Pyykkö, H. Levo, J. Rasku, V. Manchaiah, E. Kentala, (Tampere, Finland; Beaumont, USA)

17.10-17.18 Alternative medicine and non-invasive therapies for the treatment of Ménière's Disease
M. Lauriello, I. Salvi, L. Costa, M. Fusetti (L'Aquila, Italy)

17.20-17.28 Reduction of vertigo symptomatology with chronic use of weak asymmetric base-in prism spectacles (WABIPS) in Vestibular Migraine patients
E. Vente, D. Zambrano (Alphen a/d Rijn, Lekkerkerk, The Netherlands)

17.30-17.38 Cervical Specific Protocol and Results for 300 Meniere's Disease Patients Followed for a Minimum of Five Years
M.T. Burcon (Grand Rapids, USA)

17.40-17.48 Intratympanic gentamicin/dexametasone versus gentamicin alone in Ménière's Disease
D. Nuti, M. Mandalà (Siena, Italy)

17.50-17.58 Management of Ménière's disease: our experience
O. Zemirli, A. Mouzali, M.Z. Sadi, K. Ouennoughi, M.S. Haroubia (algiers, Algeria)

18.00-18.08 Usage of vasoactive therapy in cases of moderate to severe hearing disorders
D. Ranei (Niš, Serbia)

18.10-18.18 Comparative evaluation of the effect of the Meniett™ device in patients with Menière's Disease
D. Bernardeschi, E. Ferrary, D. Bouccara, O. Sterkers (Paris, France)

18.20-18.28 Intratympanic Gentamicin for Meniere's Disease: Short- and Long-term Follow-up of Two Regimens of Treatment
A.P. Casani, N. Cerchiai, E. Navari (Pisa, Italy)

18.30-18.38 Long-term results of intratympanic gentamicin in the treatment of Meniere Disease
J.J. Wazen (Sarasota, USA)
TUESDAY OCTOBER 20TH, 2015

AUDITORIUM

08.00–09.00  SAC SURGERY

Moderators: P.A. Wackym (Pittsburg, USA), R. Kania (Paris, France)

08.00–08.13  Sac surgery for treatment of Meniere Disease
R. Bento (San Paolo, Brazil)

08.15–08.28  Osteoplastic refinement in ES surgery
R.A. Bly, L.G. Duckert (Seattle, USA)

08.30–08.43  Endolymphatic duct blockage: a new era in the treatment of Menière Disease
I. Saliba, N. Gabri, M-H Asmar, D. Berbiche (Montreal, Canada)

08.45–08.58  Endolymphatic Sac Revision Surgery
M.M. Paparella (Minneapolis, USA)

09.00–10.00  PANEL: WHICH SURGICAL TREATMENT, IF ANY, FOR MENIERE’S DISEASE?

Moderator: P. Tran Ba Huy (Paris, France)

Participants: V. Darrouzet (Bordeaux, France),
P. Möller (Bergen, Norway),
S. Volkenstein (Bochum, Germany),
P. Franz (Vienna, Austria),
Y. Bayazit (Ankara, Turkey)

SAN FRANCISCO HALL

08.00–09.10  CLINICAL ISSUES 4

Moderators: M. Hultcrantz (Stockholm, Sweden), D. Passali (Siena, Italy)

08.00–08.08  Did Prosper Menière discover Menière’s Disease?
O. Michel (Brussels, Belgium)

08.10–08.18  Reevaluation of QOL in relation with symptoms of Ménière’s Disease
M. Manfrin, S. Quaglieri, E. Rebecchi, G. Locatelli, P. Canai, M. Benazzo (Pavia, Italy)

08.20–08.28  Audiological characteristics, Immunological Markers and cytokines expressions in Cochlear implant patients affected by autoimmune disorders
P. Mancini, A. Di Mario, D. Ballantyne, E. De Seta, C. Alessandri, H. Dincer (Rome, Italy)

08.30–08.38  Clinical Analysis of Patients with Spontaneous Nystagmus and Negative Video Head Impulse Test: Is it always central?
MG Moon, MB Kim, JH Ban (Seoul, Korea)

08.40–08.48  Possible role of herpesviridae family viruses in the pathogenesis and evolution of sensorineural hearing loss
W. Di Nardo, R. Anzivino, E. De Corso, P. Cattani, R. Santangelo, G. Paludetti (Rome, Italy)

08.50–08.58  Super paramagnetic nanoparticles driven by external magnetic field for targeted drug administration to the inner ear: feasibility and toxicity
G. Leterme, C. Guigou, A. Oudot, B. Collin, J. Boudon, A. Geissler, K. Belharet, A. Ferreira, A. Bozorg Grayeli (Dijon, Bourges, France)

09.00–09.08  A study for local treatment of three different polymers aimed for middle ear administration
09.15-10.00 VESTIBULAR FUNCTION AFTER CI

**Moderator:** G. Sprinzl (St Poulten, Austria)

09.15-09.28 Comparison of the Result of Caloric test vs Video Head Impulse Test in Cochlear Implant Users
A. Incelsulu (Meselik-Eskisehir, Turkey)

09.30-09.43 Vestibular function before and after cochlear implantation in patients with post lingual deafness: a prospective observational study
P.A. Abramides, R.S.M. Bittar, R.K. Tsuji, R.F. Bento (Brasilia, Brazil)

09.45-09.58 Vestibular function after cochlear implantation in partial deafness treatment
M. Sosna, K. Pietrasik, G. Tacikowska, J. Listwon, H. Skarzynski, P.H. Skarzynski (Warsaw, Poland)

10.00-10.30 Coffee break

10.30-10.50 KEYNOTE LECTURE 7

**Moderator:** M. Luntz (Haifa, Israel)

Personalized medicine for Cochlear implantation
HP Zenner (Tübingen, Germany)

11.00-12.30 PANEL: HEARING REHABILITATION IN MÉNIÈRE’S DISEASE

**Moderator:** M. Kameswaran (Chennai, India)

**Participants:** M. Luntz (Haifa, Israel), A. Ramos Macias (Las Palmas, Spain), GM. Sprinzl (St. Poulten, Austria), R. Manrique-Huarte (Pamplona, Spain)
11.00-12.30  EFFECT OF CI ON MENIERE DISEASE  

**Moderators:**  A.K. Gadre (Louisville, USA), A. Casani (Pisa, Italy)  

11.00-11.13  Strategy for end-stage Ménière’s Disease: labyrinthectomy with CI  
B. Gantz, M.R. Hansen, C. Dunn, R. Tyler (Iowa City, USA)  

11.15-11.23  Translabyrinthine vestibular nerve section and simultaneous cochlear implantation in patients with recalcitrant Menière’s Disease: preliminary report  
P. Canzi, M. Manfrin, M. Perotti, F. Aprile, S. Quaglieri, G. Locatelli, D. Fresa, M. Benazzo (Pavia, Alessandria, Italy)  

11.25-11.33  Rehabilitation of fluctuating hearing loss by cochlear implant  
D. Bernardeschi, I. Mosnier, D. Bouccara, E. Ferrary, O. Sterkers (Paris, France)  

11.35-11.43  Cochlear Implantation as therapy option in single-sided deafness and vertigo caused by M. Menière  
R. Laszig, R. Laszig, S. Arndt, A. Aschendorff, C. Hantsch, R. Beck (Freiburg, Germany)  

11.45-11.53  Spatial hearing improvement and long-term suppressive effect on tinnitus after cochlear implantation in single-sided-deaf patients with and without Ménière’s Disease  
V. van Rompaey, G. Mertens, P. Van de Heyning (Antwerp, Belgium)  

12.05-12.13  Cochlear implant in asymmetric menieric hearing loss  
D. Cuda, A. Murri (Piacenza, Italy)  

12.30-13.15  COMMENTING ON THE PRESENT GUIDELINES FOR MÉNIÈRE’S DISEASE  

**Moderator:**  M. Barbara (Rome, Italy)  

**Participants:**  
N. Ozgirgin (Ankara, Turkey) EAONO  
J.A. Lopez Escamez (Granada, Spain) BARANY  
T. Ikezono (Tokyo, Japan) JSER  
C. Cenjor (Madrid, Spain) POLITZER  
B. Gantz (Iowa City, USA) AAO-HNS  
W-H Chun (Seoul, Korea) KOREAN BALANCE SOCIETY  

13.15  Closing remarks  
M. Barbara
**AUDILOGICAL TESTING**

1. **Audiological screening in children with cerebral palsy**  
   G. Khaydarova, Kh. Shaykhova (Tashkent, Uzbekistan)

2. **Characteristics of hearing analyzer masker immunity while Meniere's Disease**  
   G. Tadevosyan, N. Lusinyan, G. Mirakyan, A. Bambabyan, A. Martirosyan, T. Pkhrikyan,  
   A. Shukuryan (Erebouni, Armenia)

3. **ecog findings in patients with Meniere’s Disease**  
   B. Mutlu, G. Kirkim, H. Evin, Y. Olgun, E. Alpin Guneri (Izmir, Turkey)

4. **Audiometric configuration following excessive noise exposure**  
   N. Atanasova, L. Ristovska (Skopje, Republic of Macedonia)

5. **Audiometric findings in patients with subjective tinnitus**  
   N. Atanasova, L. Ristovska (Skopje, Republic of Macedonia)

**CANAL DEHISCENCE**

1. **Semicircular canal malformations: clinical and instrumental findings**  
   C. Brandolini, A. Castellucci, G. Piras, A. Pirodda (Bologna, Italy)

2. **Superior canal dehiscence may induce endolymphatic hydrops: physiopathogenetic considerations about the “spontaneous plugging process” theory**  
   A. Castellucci, G. Piras, C. Brandolini, A. Pirodda (Bologna, Italy)

**CLINICAL ISSUES**

1. **A new meniere’s disease-specific quality of life survey: dokuz eylül university meniere’s disability scale**  
   B. Murtu, S. Mungan Durankaya, S. Gurkan, E. Alpin Guneri, G. Kirkim (Izmir, Turkey)

2. **Analysis of the most common causes of dizziness. Possibility treatment of patients**  
   Z. Pusara, Z. Pejic (Republika of Srpska, Bosnia and Herzegovina)

3. **Anxiety and the severity of the symptoms in patients with Ménière’s Disease**  
   A. Jotic, B. Micic, L. Cvozovic (Belgrade, Serbia)

4. **Audiovestibular findings in cerebellar pontine angle tumor**  

5. **Benign paroxysmal positional vertigo following stapedotomy**  
   N. Arsic (Belgrade, Serbia)

6. **Conservatively managed sporadic vestibular schwannoma: Audiovestibular factors influencing quality of life**  
   S. Hansen, J. Yde, S. Stangerup, M. Møller, C. Workman, P. Cayé-Thomasen (Copenhagen, Denmark)

7. **Evaluation of urinary deoxyribonucleotide levels and their correlation with temporal bone HRCT and density metric data in otosclerosis**  
   P. Tuncbilek Ozmane, N. Karabay, G. Kirkim, E. Alpin Guneri (Izmir, Turkey)

8. **Forms of vertigo in enclosed tympanum chronic mastoiditis**  
   S. Serban, M. Radulescu, A. Rusecu, C. Draghi (Bucurest, Rumenia)

9. **Intravestibular schwannoma: symptomatic treatment with intratympanic gentamycin**  
   L. Volpini, E. Covelli, C. Filippi, S. Monini, M. Barbara (Rome, Italy)

10. **Manifestation of Lermoyez’s syndrome in Ménière’s disease patient**  
    Š. Kordiš, N. Božanić Urbančič, M. Hirbar and S. Battelino (Ljubljana, Slovenia)

11. **Meniere’s disease presented with micro vascular compression of the vestibulocochlear nerve**  
    Kh. Ouennoughi, M.S. Haraoubia, A. Mouzali, K. Kanoun, L. Boublata, D. Ioualalëne, O. Zemiri (Algiers, Algeria)

12. **Otitis media and Ménière’s Disease**  
    A. Djeric (Belgrade, Serbia)

13. **Psychological evaluation of the patients with vertigo due to otoliths organ**  
    T. Kobayashi, T. Seo, S. Ko, M. Kitano, K. Doi (Osaka, Japan)

14. **Relationship between clinical properties and audiovestibular findings in patients with Meniere’s Disease**  
    B. Murtu, G. Kirkim, Fulya Kocyigit, S. Mungan Durankaya, S. Gurkan, Y. Olgun, E. Alpin Guneri (Izmir, Turkey)

15. **Reversible inner ear symptoms in destructive temporal bone lesions**  
    N. Yehudai, M. Luntz (Haifa/Tel Aviv, Israel)
14. Sleep and dizziness handicap inventory profiles in Ménière's Disease and vestibular neuronitis
   (Kochi, Japan)

15. The many faces of migraine – auditory and vestibular presentation: a case study
   B. Ceranic
   (London, UK)

16. The risk of misdiagnosis between Chronic Subjective Dizziness (CSD) and Ménière Disease (MD): a psychometrics analysis
   A. Chiarella, C. Petrolo, R. Riccelli, E. Cassandro
   (Catanzaro/Salerno, Italy)

17. Tinnitus and spondyloarthrosis: strong confection between ENT and Reumatology
   K. Anjeze, K. Julia, B. Jonida
   (Tirana, Albania)

COCHLEAR IMPLANT

1. Cochlear implantation as a method of rehabilitation of tinnitus
   E. Levin, S. Levin, V. Kuzovkov, V. Voronov
   (St. Peterbourgh, Russia)

2. Cochlear implantation in a patient with Paget disease
   N. Yehudai, A. Wolfovitz, T. Shpak, R. Shihada, M. Luntz
   (Haifa, Israel)

3. Features sound processor settings in patients after ABI
   S. Levin, I. Koroleva, V. Kuzovkov, E. Levinia, V. Voronov
   (St. Peterbourgh, Russia)

4. Inner ear abnormalities in cochlear implant candidates
   A. Mouzali, M. S. Haraoubia, K. Ouennaghi, M. Z. Sadi, O. Zemirli
   (Algiers, Algeria)

5. Middle cranial fossa vestibular neurectomy for intractable Ménière’s Disease
   (Osaka, Japan)

6. Outcomes of cochlear implantation in children with severe and very severe malformations of the inner ear and the auditory nerve
   N. Yehudai, S. Masoud, T. Shpak, R. Khanifès, M. Luntz
   (Haifa, Israel)

7. Performance after revision surgery for cochlear implant soft failures
   N. Yehudai, T. Shpak, S. Masoud, R. Khanifès, M. Luntz
   (Haifa, Israel)

8. Persistent vestibular symptoms after cochlear implantation - clinical overview
   M. Sośna, K. Pietrasik, G. Tacikowska, P.H. Skarżyński, H. Skarżyński
   (Warsaw, Poland)

9. Residual hearing in candidates for cochlear implantation
   Y. Garti, N. Yehudai, T. Shpak, M. Luntz
   (Haifa, Israel)

10. Setting expectations for speech understanding in quiet and in noise in straightforward adults cochlear implant candidates
    (Haifa, Israel)

COMBINED TREATMENT

1. Cochlear and vestibular effects of combined intratympanic dexamethasone and gentamycin
   E. Alpin Güneri, Y. Olgun, M. Aslier, D. Nuti, G. Kirkim, S. M. Durankaya, E. Kolatan, S. Aktaş,
   F. Trabalzini, H. Ellidokuz, O. Yilmaz, M. Mandalı
   (Izmir, Turkey; Siena, Italy)

2. Transtympanic inner ear drug therapy
   A. Belal
   (Alexandria, Egypt)

ENDOLUMPHATIC SAC

1. Cystic fibrosis transmembrane conductance regulator in the endolymphatic sac of the rat
   B. Matsubara, T. Miyashita, R. Inamoto, H. Hoshikawa, N. Mori
   (Kagawa/Osaka, Japan)

2. Human endolymphatic sac and cochlear water channels - Implications to inner ear fluid homeostasis and mechanism of Meniere's Disease
   W. Liu, H. Rask-Andersen
   (Uppsala, Sweden)

3. Prox1 expression in the endolymphatic sac revealed by whole-mount fluorescent imaging of prox1-GFP transgenic mice
   T. Miyashita, J. L. Burford, Y. K. Hong, H. Georgyvan, L. Lam, H. Hoshikawa, N. Mori, J. Petti-Peterdi
   (Kagawa/Osaka, Japan; Los Angeles, USA)

4. The human endolymphatic sac is an intracranial endocrine gland
   M. Nue Moller, S. Kirkeby, J. Vikesa, F. C. Nielsen, P. Caye-Thomasen
   (Copenhagen, Denmark)

5. The human vestibular aqueduct and LVAS – anatomical and radiological assessment
   C.K. Nordström, H. Rask-Andersen
   (Uppsala, Sweden)
GENETICS
1. Exome sequencing data involve multiple genes and pathways in familial Meniere’s Disease
   L. Frejo, T. Requena, C. Martin-Sierra, S. Cabrera, J. A. Lopez-Escamez (Granada, Spain)
2. Extreme tinnitus phenotype in Meniere’s Disease
   J.M. Espinosa-Sanchez, A. Batuecas-Caletrio, H. Sanchez-Gomez, J.A. Lopez-Escamez (Granada, Spain)
3. Genetic aspects and clinical characteristics of familial Ménière’s disease in a South Korean population
   J. Woong Kim, J. Hyuk Han, J. Mi Lee, S. Huhn Kim (Seoul, Korea)
4. Identification and functional analysis of THAP1 gene segregating vestibular phenotype in monozygotic twins with Meniere’s Disease
   A. Martin-Sierra, T. Requena, L. Frejo, A. Ji, J. A. Lopez-Escamez (Granada, Spain)

GENTAMYCIN
1. Intratympanic gentamycin in a grade 1 vestibular schwannoma
   V. Van Rompaey, T. Menovsky, P. Van de Heyning (Antwerp, Belgium)
2. Long-term hearing outcome after intratympanic gentamycin instillation for Ménière’s Disease
   S. Verhoeven, V. Van Rompaey, O. Vanderveken, P. Van de Heyning (Antwerp, Belgium)
3. Semicircular canal’s function in patient with Ménérie’s disease treated with low-dose intratympanic gentamycin
   G. Tacikowska, K. Pietrasik, H. Skarzynski (Warsaw, Poland)

HEARING AIDS
1. Quality of life before and after hearing aids
   HS. Chew, YM. Heng, A. Leong (Singapore)

IMAGING
1. Cost effectiveness of using contrast-enhanced magnetic resonance imaging for screening unilateral hearing loss
   F.N. Ardiç, F. Tümkay, K. Ağladaoğlu, M. Şentürk, O. Kara, Y. Kuroğlu (Denizli, Turkey)
2. High signal on 3D flair, a predictable factor for progression to Meniere’s Disease in sudden hearing loss
   S. Hun Lee, C. Joo Yang, J. Hyun Lee, J. Ho Ahn (Seoul, Korea)

IMMUNE-MEDIATED DISEASE
1. Microglia in Meniere’s syndrome
   F. Santos, A. Eckhard, A. DiStadio, J. O’Malley, M. J. McKenna (Boston, USA)
2. Unilateral neurosensorial hearing loss and Multiple Sclerosis
   K. Anjeze, B. Jonida (Tirana, Albania)
3. Unilateral sensorineural hearing loss as immune-mediated inner ear disease
   F. Atturo, M. Barbara, S. Monini (Rome, Italy)

INNER EAR FLUIDS DYNAMICS
1. Adrenergic stimulation-mediated transepithelial current from human endolymphatic sac epithelium
   A. Gyung Kim, S. Park, J. Eun Yoo, J. Young Choi, S. Huhn Kim (Seoul, Korea)
2. Barotraumatic perilymphatic fistula: proposed approach to diagnosis and management
   J. Eun Choi, J. Joon Moon, W. Chung, Y. Cho, S. Hwa Hong (Seoul, Korea)
3. The inner ear - a novel target for insulin action and resistance – implications for diabetes
   E. Degerman, R. in ‘Zandt, M. Magnusson (Lund, Sweden)
MEDICAL TREATMENT

1. Optimal management of Ménière’s Disease

2. Treatment of peripheral vestibular vertigo
   K. Shaykhova, G. Khaydarova (Tashkent, Uzbekistan)

OTOTOXICITY

1. Platinum-induced ototoxicity in children: comparison of different ototoxicity classification
   G. Kirkim, Y. Olgun, S. Mungan Durankaya, D. Kizmaz Cakir, D. Ince, K. Mutafoglu, N. Olgun, E. Alpin Guneri (Izmir, Turkey)

2. Ototoxicity of parenterally administered gentamycin - case report
   N. Atanasova, V. Stojevska, I. Mihajlovska Shulevska, D. Stoimenov (Skopje, Republic of Macedonia)

PRESSURE TREATMENT

1. Effect of transtympanic ventilation tube insertion in intractable Ménière’s Disease
   T. Kuruma, T. Tanigawa, M. kishimoto, I. Uchida, O. Tetsuya, H. Ueda (Nagoya, Japan)

STEROID TREATMENT

1. Evaluating effectiveness of intratympanic dexamethasone injection of Ménière’s patients with alteration of electrocochleography
   N. Yazdani (Teheran, Iran)

SUDDEN DEAFNESS

1. Prognosis of severe to profound idiopathic sudden sensorineural hearing loss
   C. Lee, S. Jo, Y. Cho (Gwanju, Korea)

2. Relationship between hearing threshold at the affected and unaffected ear in unilateral Ménière’s Disease
   R. Albera, A. Canale, C. Cassandro, A. Albera, A. Sammartano, V. Boggio, M. Crutti, F. Dagna (Torino, Italy)

3. Vestibular schwannoma in sudden sensorineural hearing loss patients
   YS. Park, IW. Lee, IC. Nam, DH. Kim, EJ. Jeon (Incheon, Korea)

SURGERY

1. Endoscopic inlay butterfly (cartilage) tympanoplasty
   K. Aykal, F. Tumkaya, C.O. Kara, F.N. Ardic (Denizli, Turkey)

2. Otoneurological assessment in long term follow up after vestibular neurectomy for Ménière’s Disease
   A. Canale, F. Caranzano, M. Lanotte, F. Calamo, F. Dagna, L. Salonia, M. Lacilla, M. Boldreghini, R. Albera (Turin, Italy)

3. Outcome of attic reconstruction after minimal incision anticoagostomy approach laser surgery for congenital cholesteatoma (MILO) - Surgical experience from 400 cases
   C. Ho Lee, H. Kim (Gyeonggi-do, Korea)

4. Temporary canal wall removal in primary inner ear schwannomas and B2 glomus tympanicum tumors
   V. Van Rompaey, P. Van de Heyning (Antwerp, Belgium)

5. Vestibular Neurectomy: retrosigmoid or retrolabyrinthine approach?
   J. Yang, H. Jia, Y. Liu, Z. Zhang, Z. Wang, Q. Huang, H. Wu (Shanghai, China)
TREATMENT

1. **Difficulties of psychological therapy in patients with Ménière’s Disease**
   L. Haraoubia, K. Ouennoughi, L. Beridja, M.S. Haraoubia, O. Zemirli (Algiers, Algeria)

2. **Intracochlear drug delivery by injections through the round window membrane: measures to improve drug retention**
   S. Plontke (Halle, Germany)

VESTIBULAR TESTING

8. **Vestibular function in partial and total deafness**
   M. Sosna, K. Pietrasik, G. Tacikowska, J. Listwon, M. Matuszewska, H. Skarzynski, P.H. Skarzynski (Warsaw, Poland)

9. **Vestibular neuritis according to VHIT testings. Clinical entities and prognostic factors**
   R. Glatre, C. Hautefort, B. Verillaud, C. Domange, P. Herman, R. Kania (Paris, France)

10. **White & gray matter differences between visual vertigo patients and healthy controls: preliminary results**
    A. Van Ombergen, B. Jeurissen, V. Van Rompaey, S. Vanhecke, F. Vanhevel, J. Sidhu, S. Sunaert, P.H. Van de Heyning, P.M. Parizel & F.L. Wuyts (Antwerp/Ledege/Leuwen, Belgium)

1. **Abnormality of doll’s eyes response to head tilt in roll in patients with Ménière’s Disease**
   T. Okada, Y. Tanaka, K. Ido, M. Fukasawa, Y. Miyamoto, M. Nakamura and I. Koizuka (Kawasaki City/Yokohama City)

2. **Comparative evaluation between caloric test, VEMP and DDPAOE in diagnosing Ménière’s Disease**
   M.Z. Sadi, A. Mouzali, Kh. Ouennoughi, M.S. Haraoubia, O. Zemirli (Algiers, Algeria)

3. **Furosemide loading vestibular evoked myogenic potentials can detect having endolymphatic hydrops - Up-to-date experience**
   T. Seo, K. Shiraishi, T. Kobayashi, M. Kitano, K. Doi (Osakasayama, Japan)

4. **Is the cause of a vertigo attack Ménière’s disease or vestibular neuritis? Objective measurements give the answer**
   L. Manzari, A.M. Burgess, H.G. MacDougall, I.S. Curthoys (Cassino, Italy; Sydney, Australia)

5. **Isolated and combined semicircular canal dysfunction in patients with unilateral vestibular schwannoma**
   A.J. Beynon (Nijmegen, The Netherlands)

6. **Maturation of subjective visual vertical in children**
   M. Toupet, C. Van Nechel, A. Bozorg Grayeli (Paris, France)

7. **The patients with Meniere’s disease result in the discrepancy between video head impulse test and caloric testing**
   M. Kitano, T. Seo, K. Shiraishi, T. Kobayashi, K. Doi (Osaka, Japan)
Meniere's Disease
Inner Ear Disorders
7th International Symposium on
ROME, Italy October 17th-20th, 2015

PLATINUM SPONSOR
Mylan
Seeing is believing
BGP Products Srl

GOLD SPONSORS

SILVER SPONSOR

AMMI onlus
ASSOCIAZIONE MALATI MENIERE INSIEME
ECHODIA
Nano Signal Technologies

SPONSORS & EXHIBITORS

GTI TEAM
MED-EL
MEDIFOOD
ONTOSICOM
OTONOMY
Pharma Scandinavia

Cochlear®

ECHODIA
Nano Signal Technologies

HTS CREW
We work to improve your LIFE

UDISENS®
UN BENE PER L'UOMO

Medtronic

Thieme
ONSITE REGISTRATION FEES
Full registration physician € 750,00
Residents*, PhD students, other professions €200,00
Accompanying Person - social program only € 200,00

The fees include
- Access to scientific sessions and exhibition area
- Congress kit and name badge
- Final program
- Abstract book
- Certificate of attendance
- Coffee breaks
- Welcome Cocktail on October 17th
- Congress Dinner on October 19th *

*Not included for Residents, PhD students, other professions fee
Dinner ticket: € 90,00

ITALIAN CME ACCREDITATION
The 7th International Symposium on Menière's Disease and Inner Ear Disorders has been accredited by the Italian Ministry of Health.

ITALIAN CME CATEGORIES (only for italian participants)
The congress has been accredited for the following categories:
- PHYSICIAN: general surgery; ent; audiometry & phoniatrics;
- DOCTOR OF AUDIOLOGY;
- HEARING HEALTHCARE PROFESSIONAL
- SPEECH THERAPIST PROFESSIONAL

CME ITALIAN CREDITS: 14,5
The issue of the Italian CME certificate is subordinate to:
- 100 % of attendance in the entire congress
- CME questionnaire: scaled score of at least 80% of correct answers
- Correspondence of professional category accredited
Delegate who will fulfill all the above requirements will receive an email in order to complete the CME questionnaire online.

OFFICIAL LANGUAGE
English

CERTIFICATE OF ATTENDANCE
Each delegate will receive the certificate of attendance at the registration desk at the end of the congress.

UEMS
THE EUROPEAN ACCREDITATION COUNCIL FOR CME (EACCME®)
The 7th INTERNATIONAL SYMPOSIUM ON MENIERE’S DISEASE AND INNER EAR DISORDERS has been accredited by European Accreditation Council for Continuing Medical Education.

EACCME credits are recognized Europe-wide and in North America. They can be converted into their national equivalent by contacting your national CME Authority.
EACCME credits are recognized by the American Medical Association (AMA) towards Physicians Recognition Award (PRA).
18 European CME Credits (ECMEC) have been assigned for the entire congress. The certificate will be available in the congress bag.